INTRODUCTION AND OBJECTIVES: MRI fusion biopsy (FusBx) of the prostate improves the overall detection rate of clinically significant prostate cancer (CSPC) compared to standard template biopsy (Std-Bx). MRI cognitive fusion biopsy (Cog-Bx) can also be used to target lesions visible on MRI, but without the need for Fus-Bx equipment. We prospectively compare detection of prostate cancer (PC) between Fus-Bx and Cog-Bx modalities.
METHODS: From July 2017eSeptember 2018 patients with suspected PC, or who were on an AS protocol for low risk PC, underwent a multiparametric 3.0 Tesla prostate MRI. Patients with an identifiable lesion PiRADS 3 or greater were identified for both cognitive and MRI fusion biopsy. Each patient underwent targeted Cog-Bx of the suspicious lesion, immediately followed by targeted Fus-Bx using the UroNav image-guided stereotactic biopsy system, and then Std-Bx. Concordance rates between the Fus-Bx and Cog-Bx were described, and agreement between modalities was assessed using Cohen's kappa coefficient. Sensitivity was calculated for each modality against the "gold standard" defined as the highest Gleason grade group (GGG) detected using all three modalities (Std-Bx, Cog-Bx, and FusBx). CSPC was defined as GGG 2 or greater. High grade prostate cancer (HGPC) was defined as GGG 4 and 5.
RESULTS: 40 patients were included in the analysis. The mean age was 66.6 years (sd: 8.1). Median PSA was 8.41 ng/dl (IQR: 5.67-13.37). Median gland volume was 45.6cc (IQR: 34.25-74.55). Median lesion size was 1.15cm in largest dimension (IQR: 0.83-1.40), and 0.63cc in volume (IQR: 0.30-1.80). Median number of cores examined was 16 (IQR: 14-17). 32 patients (80%) had positive biopsies. 21 patients (52.5%) had CSPC. 7 patients (17.5%) had HGPC. Concordance between Fus-Bx and Cog-Bx was 85.0% for detection of any cancer, 92.5% for detection of CSCP, and 100% for HGPC. A high degree of agreement between modalities was shown with Cohen's kappa coefficient (Any cancer: 0.65; CSPC: 0.85; HGPC: 1.00). The targeted modalities had similar sensitivities for detection of any cancer (CogBx: 0.75; Fus-Bx: 0.72), CSPC (CogBx: 0.95; Fus-Bx: 0.86), and HGPC (Cog-Bx: 1.00, Fus-Bx: 1.00). Sensitivity improved significantly when both Cog-Bx and Fus-Bx were analyzed together (Any cancer: 0.84; CSPC: 1.00; HGPC: 1.00).
CONCLUSIONS: Concordance rates were high between CogBx and Fus-Bx. Sensitivities for each test were similar for detection of any cancer, CSPC, and HGPC. Both Cog-Bx and Fus-Bx detected CSPC and HGPC with high sensitivity. Fus-Bx did not demonstrate an objective benefit over Cog-Bx in our cohort.
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MP30-16 LIMITED ROLE FOR A DEDICATED MRI FUSION BIOPSY PROVIDER IN DETECTING PROSTATE CANCER
Matthew Gay*, Joshua Langston, Douglas Kelly, Norfolk, VA INTRODUCTION AND OBJECTIVES: Multiparametric MRI (mpMRI) transrectal ultrasound (TRUS) fusion-guided biopsy (Fbx) has been shown to be superior to standard 12-core TRUS-guided biopsy (Sbx) in detecting clinically significant (CS) prostate cancer (PCa). The effect of provider variability on prostate cancer detection using mpMRI Fbx has yet to be established. We hypothesize that there is no statistically significant difference between the yields of PCa detection using Fbx in the region of interest (ROI) on mpMRI between providers.
METHODS: A retrospective chart review was conducted on the first 250 mpMRI-TRUS Fbx performed at our institution. All patients underwent mpMRI at 1 of 2 imaging centers. Suspicious lesions on mpMRI were scored according to PI-RADSv2. Three providers performed Sbx and Fbx according to standardized clinical pathways using UroNav Fusion Biopsy System (Phillips, Invivo). Patients were assigned to each provider randomly, based on the chronological order in which the consults were received. CS PCa was defined as a tumor containing Gleason score (GS) 3þ4 or higher PCa. Fisher's exact tests were performed to assess if provider variability was significant.
RESULTS: The overall (Fbx and Sbx) cancer detection rate (CDR) was 56% (n [ 250). The CDR for Fbx was 45% and the CS CDR was 37%. The CDR for Sbx was 38% and the CS CDR was 28%. Fbx missed 21% PCa; however, only 11% CS PCa. Sbx missed 32% PCa and 25% CS PCa. In Fbx, PCa detection rates for PI-RADS 3/4/5 lesions were 17%, 53%, and 77%, respectively. In Fbx, CS PCa detection rates for PI-RADS 3/4/5 lesions were 11%, 42%, and 69%, respectively (Table 1) . In Fbx, PCa detection rates for PI-RADS 3 lesions were 7%, 9%, and 30% (p [ 0.036) for provider 1, 2, and 3, respectively. In Fbx, PCa detection rates for PI-RADS 4 lesions were 52%, 54%, and 53% (p [ 0.99) for provider 1, 2, and 3, respectively. In Fbx, PCa detection rates for PI-RADS 5 lesions were 80%, 80%, and 72% (p[0.83) for provider 1, 2, and 3, respectively (Table 2) .
CONCLUSIONS: In PI-RADS 4 and 5 lesions, provider variability did not affect detection of prostate cancer, suggesting that Fbx yield in PI-RADS 4 and 5 lesions is provider independent. There was variability in prostate cancer detection with Fbx in PI-RADS 3 lesions. Further research is needed to determine the etiology of this variation and methods to increase concordance between providers.
